MAPK3 and cancer: We found that TGFβ stimulation failed to activate canonical (P‐SMAD2), or non‐canonical (P‐ERK1/2 and P‐P38) TGFβ signaling in the TGFβR2‐deficient cancer cells (Tgfbr2mut1 and Tgfbr2mut2) compared to the control cell line (Tgfbr2wt) (Fig 6F).